CanSino Biologics Dirección

Dirección controles de criterios 2/4

El CEO de CanSino Biologics' es Xuefeng Yu, nombrado en Jan 2009, tiene una permanencia de 15.25 años. posee directamente un 7.24% de las acciones de la empresa, con un valor de HK$605.69M. La antigüedad media del equipo directivo y de la junta directiva es de 6.2 años y 4.4 años, respectivamente.

Información clave

Xuefeng Yu

Chief Executive Officer (CEO)

CN¥4.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	15.3yrs
Participación del CEO	7.2%
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Xuefeng Yu (58 yo)

15.3yrs

Permanencia

CN¥4,940,000

Compensación

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Xuefeng Yu	Co-Founder	15.3yrs	CN¥4.94m	7.24% CN¥ 673.1m
Tao Zhu	Co-Founder	15.3yrs	CN¥4.98m	7.24% CN¥ 673.1m
Dongxu Qiu	Co-Founder	15.3yrs	CN¥4.61m	6.93% CN¥ 644.5m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6yrs	CN¥4.91m	sin datos
Jing Wang	Chief Commercial Officer	2.7yrs	CN¥3.97m	sin datos
Chunlin Xin	Senior Director of New Technology Department	6.5yrs	sin datos	sin datos
Yonghui Wu	Vice President of Marketing	no data	sin datos	sin datos
Jin Cui	Board Secretary	5.2yrs	sin datos	sin datos
Ming King Chiu	Joint Company Secretary	5.2yrs	sin datos	sin datos

6.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6185 es experimentado (6.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xuefeng Yu	Co-Founder	15.3yrs	CN¥4.94m	7.24% CN¥ 673.1m
Shou-Bai Chao	COO, Deputy GM & Executive Director	5.9yrs	CN¥4.91m	sin datos
Jing Wang	Chief Commercial Officer	2.6yrs	CN¥3.97m	sin datos
George R. Siber	Co-Chair of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Shuifa Gui	Independent Non-Executive Director	4.5yrs	CN¥300.00k	sin datos
Liang Lin	Non-Executive Director	10.8yrs	sin datos	sin datos
David Briles	Member of Scientific Advisory Board	no data	sin datos	sin datos
Luis Barreto	Member of Scientific Advisory Board	no data	sin datos	sin datos
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	sin datos	sin datos
Jianzhong Liu	Independent Non-Executive Director	4.5yrs	CN¥300.00k	0.00040% CN¥ 37.2k
Liming Li	Co-Chair of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Leung Cheung Yiu	Independent Non-Executive Director	no data	sin datos	sin datos

4.5yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 6185 se considera experimentada (4.4 años de antigüedad promedio).

CanSino Biologics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Non-Executive Director recently sold HK$3.4m worth of stock

Less than half of directors are independent

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

Recent updates

First quarter 2024 earnings released: CN¥0.69 loss per share (vs CN¥0.57 loss in 1Q 2023)

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Full year 2023 earnings released: CN¥6.01 loss per share (vs CN¥3.68 loss in FY 2022)

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings released: CN¥5.87 loss per share (vs CN¥3.68 loss in FY 2022)

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

First quarter 2023 earnings released: CN¥0.57 loss per share (vs CN¥0.49 profit in 1Q 2022)

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Investor sentiment improved over the past week

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.06 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

CanSino Biologics Inc. to Report Q1, 2022 Results on Apr 28, 2022

Investor sentiment deteriorated over the past week

Cansino Biologics Inc. Proposes Dividend for the Financial Year Ended 31 December 2021

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Full year 2021 earnings released: EPS: CN¥7.74 (vs CN¥1.72 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CanSino Biologics Inc. announces Convidecia Approve as Heterologous Booster in China

CanSino Biologics Inc. (SEHK:6185) announces an Equity Buyback for CNY 300 million worth of its shares.

Investor sentiment deteriorated over the past week

CanSinoBIO's Shows Encouraging Results for Inhaled COVID-19 Vaccine as Heterologous Booster

CanSino Biologics Inc. Announces Approval for its MCV4 Product Menhycia in China

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. Announces the National Medical Products Administration of China Grants New Drug Approval to Menhycia

CanSino Biologics Inc. Announces Convidecia™ Phase III Results Published in The Lancet

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Non-Executive Director Qiang Xu has left the company